An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells
© 2022 The Authors..
Spacing the first two doses of SARS-CoV-2 mRNA vaccines beyond 3-4 weeks raised initial concerns about vaccine efficacy. While studies have since shown that long-interval regimens induce robust antibody responses, their impact on B and T cell immunity is poorly known. Here, we compare SARS-CoV-2 naive donors B and T cell responses to two mRNA vaccine doses administered 3-4 versus 16 weeks apart. After boost, the longer interval results in a higher magnitude and a more mature phenotype of RBD-specific B cells. While the two geographically distinct cohorts present quantitative and qualitative differences in T cell responses at baseline and after priming, the second dose led to convergent features with overall similar magnitude, phenotype, and function of CD4+ and CD8+ T cell responses at post-boost memory time points. Therefore, compared to standard regimens, a 16-week interval has a favorable impact on the B cell compartment but minimally affects T cell immunity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
iScience - 26(2023), 1 vom: 20. Jan., Seite 105904 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nicolas, Alexandre [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological sciences |
|---|
| Anmerkungen: |
Date Revised 14.08.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.isci.2022.105904 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351053859 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351053859 | ||
| 003 | DE-627 | ||
| 005 | 20231226050416.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.isci.2022.105904 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351053859 | ||
| 035 | |a (NLM)36594081 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nicolas, Alexandre |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. | ||
| 520 | |a Spacing the first two doses of SARS-CoV-2 mRNA vaccines beyond 3-4 weeks raised initial concerns about vaccine efficacy. While studies have since shown that long-interval regimens induce robust antibody responses, their impact on B and T cell immunity is poorly known. Here, we compare SARS-CoV-2 naive donors B and T cell responses to two mRNA vaccine doses administered 3-4 versus 16 weeks apart. After boost, the longer interval results in a higher magnitude and a more mature phenotype of RBD-specific B cells. While the two geographically distinct cohorts present quantitative and qualitative differences in T cell responses at baseline and after priming, the second dose led to convergent features with overall similar magnitude, phenotype, and function of CD4+ and CD8+ T cell responses at post-boost memory time points. Therefore, compared to standard regimens, a 16-week interval has a favorable impact on the B cell compartment but minimally affects T cell immunity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biological sciences | |
| 650 | 4 | |a Components of the immune system | |
| 650 | 4 | |a Immunology | |
| 700 | 1 | |a Sannier, Gérémy |e verfasserin |4 aut | |
| 700 | 1 | |a Dubé, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Nayrac, Manon |e verfasserin |4 aut | |
| 700 | 1 | |a Tauzin, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Painter, Mark M |e verfasserin |4 aut | |
| 700 | 1 | |a Goel, Rishi R |e verfasserin |4 aut | |
| 700 | 1 | |a Laporte, Mélanie |e verfasserin |4 aut | |
| 700 | 1 | |a Gendron-Lepage, Gabrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Medjahed, Halima |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Justine C |e verfasserin |4 aut | |
| 700 | 1 | |a Brassard, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Niessl, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Gokool, Laurie |e verfasserin |4 aut | |
| 700 | 1 | |a Morrisseau, Chantal |e verfasserin |4 aut | |
| 700 | 1 | |a Arlotto, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Tremblay, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Martel-Laferrière, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Finzi, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Greenplate, Allison R |e verfasserin |4 aut | |
| 700 | 1 | |a Wherry, E John |e verfasserin |4 aut | |
| 700 | 1 | |a Kaufmann, Daniel E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t iScience |d 2018 |g 26(2023), 1 vom: 20. Jan., Seite 105904 |w (DE-627)NLM285332627 |x 2589-0042 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:1 |g day:20 |g month:01 |g pages:105904 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.isci.2022.105904 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 1 |b 20 |c 01 |h 105904 | ||